**Alpha-Lipoic Acid and Its Clinical Applications**

Burton M. Berkson, MD, MS, PhD

Relevant financial relationships in the past twelve months by presenter or spouse/partner:
- Employment: Integrative Medical Center of New Mexico
- Grant/Research Support: N/A
- Consultant: Livon Labs Supplements
- Stock Shareholder: N/A
- Other: Bio-tech Products Consultant

Status of FDA devices used for the material being presented: N/A
Status of off-label use of devices, drugs or other materials that constitute the subject of this presentation:

---

**Objectives**

- Describe the structure and metabolic function of Alpha-Lipoic Acid.
- Present some of the history of Alpha-Lipoic Acid as an investigational drug and as a nutraceutical.
- Describe the role of Alpha-Lipoic Acid in mitochondrial function.
- Characterize the role of Alpha-Lipoic Acid in liver disease.
- Portray the role of Alpha-Lipoic Acid in cancer therapy.
- Describe the role of Alpha-Lipoic Acid in auto-immune disease.

---

**EUKARYOTIC RESPIRATION**

- **GLYCOLYSIS** (cytoplasm)
  - pyruvate dehydrogenase (ALA)

  **KREBS CYCLE** (mitochondrion)

**ACTIONS OF ALA**

- FREE RADICAL SCAVENGER
- NOURISHMENT OF GENE EXPRESSION
- PREVENTS ISCHEMIA-REPERFUSION INJURY
- STIMULATES NEURAL REGENERATION
- IMPROVES IMMUNE RESPONSE
- HEALS INJURED ORGAN TISSUES
- RETAINS YOUTH FUNCTION
- DATA SHARING FACTOR: FOOD TO ENERGY

---

**Glycolysis:**

- **anaerobic**

  Occurs in the cytoplasm.
  Glucose is converted to pyruvate. No oxygen is required.

  Cancer cells typically just go this far and convert pyruvate to lactate even in the presence of O2.
Alpha lipoic acid is fundamental for the conversion of food to energy. It is my understanding that ALA is the rate-limiting agent for the production of energy from food in aerobic cells.

Pyruvate Dehydrogenase Kinase (PDK) inhibits the enzyme complex (PDH) that converts Pyruvate into Acetyl CoA. Alpha Lipoic Acid decreases the rate of action of Pyruvate Dehydrogenase Kinase.

Pyruvate dehydrogenase kinase inhibits Pyruvate Dehydrogenase.

More available Pyruvate Dehydrogenase results in increased Pyruvate being directed into the Krebs Cycle over the conversion of Pyruvate to Lactate.


Alpha Lipoic Acid is important for the acetylation of histones in the cell nucleus. Alpha Lipoic Acid helps repair DNA.
Since a young person produces enormous amounts of ALA, what happens when you feed a Thanksgiving dinner to a 2 year old child; or an 80 year old man?

What if a mitochondrion receives too much ALA? Lipoic acid LD50 Studies by Drs Vigil and Couch.


• Following these studies I was asked to observe the necropsies and perform the electron microscopy work on the damaged tissues at NMSU.

• I observed extensive necrotic lesions in the liver, kidneys, heart, and the large muscles of the extremities.

Healthy primate mitochondrion (hepatocyte)

Mitochondria from animals who had received excessively high doses of ALA became extremely edematous, and demonstrated a disruption of all the crucial structures.

These mitochondria did not exhibit the regular double membrane wall structure, but showed a coalescence of these structures with a deliquescence of membranes thus exhibiting a complete disruption of normal ultrastructure.

Primate hepatocyte mitochondria following a LD50 IV lipoic acid dose of about 90mg/kg
LIVER MITOCHONDRIA SUFFERED SEVERE STRUCTUAL DAMAGE BY EXTREMELY HIGH DOSES OF INTRAVENOUS ALPHA LIPOIC ACID

Global Advances in Health and Medicine January, 2014, volume 3 number 1

Michael Vigil MD
Adjunct Associate Research Professor, Department of Biochemistry NMSU
Burton M. Berkson MD PhD
Former Assistant Professor, Rutgers University
Former Assistant Professor, Chicago State University
Faucilitator, The Integrative Medical Center of New Mexico
Adjoint Professor, NMSU
Adjoint Professor, Oklahoma State Univ College of Medicine
vigilm@nmsu.edu (corresponding author)

Ana Patricia Garcia DVM MS PhD
Associate Research Professor and Veterinary Pathologist Yerkes Assistant Professor, Department of Pathology and Laboratory Medicine Emory University School of Medicine

With appropriate ALA levels, the mitochondrion functions normally.

If the mitochondrion does not obtain sufficient ALA, it suffers, and the organism dies.

It is interesting to note that therapeutic doses of intravenous ALA helps a liver regenerate but extremely high doses of the same agent causes liver necrosis.

Of course, excessive and unreasonable amounts of any substance given intravenously can be lethal, including water and salt.

Does ALA help regenerate livers?

1st large scale clinical trial with IV alpha-lipoic acid at NIH
(Bartter, Berkson, et. al. 1977-1980)
We reported in 3 publications that we treated 79 people waiting for liver transplant surgery (acute hepatic necrosis) and 75 regenerated their livers with just the administration of intravenous Alpha-lipoic acid.

I was appointed by the FDA principal investigator for alpha lipoic acid as a prescription drug in 1983. That lasted 23 years.

If IV ALA reverses acute liver disease, will it reverse chronic liver disease, for example hepatitis C?
GERMAN JOURNAL OF INTERNAL MEDICINE ARTICLE


I took 3 cirrhotic hepatitis C patients in the process of liver transplant evaluation at University Hospital and administered ALA, silymarin and selenium (inhibition of replication). The 3 recovered normal liver function within 6 months.

Conclusion of my 1999 paper. I offered a more conservative approach to the treatment of hepatitis C. That is exceedingly less expensive. One year of the triple anti-oxidant therapy described in this paper costs less than $3,000, as compared to more than $500,000 a year for liver transplant surgery.

Are there other diseases that ALA might help?


Lipoic acid is a potential therapy for chronic diseases associated with oxidative stress. Most chronic diseases are associated with OS.

Lipoic Acid prevents ischemia-reperfusion injury


Alpha-Lipoic acid protects against ischemia reperfusion injury following cerebral ischemia.

What about ALA and diabetes?


Oxidative stress in the aging rat heart is reversed by supplementation with alpha-lipoic acid.

Henriksen et al. published the first human study to show that ALA increases insulin stimulated glucose movement into the cell, and out of the blood stream, in diabetes.

This study demonstrated that alpha-lipoic acid is an effective treatment for peripheral and autonomic diabetic neuropathy and also diabetic neuropathy of the cranial nerves leading to full recovery of the patients.

At the Integrative Medical Center of New Mexico, we treat diabetic neuropathies with IV ALA every day.

What about ALA and cancer?

"All hallmarks of cancer including the Warburg effect can be linked to impaired respiration and energy metabolism." These are "downstream effects of damaged mitochondrial function."

Thomas Seyfried Cancer As a Metabolic Disease (Wiley, 2012)

Warburg O. The chemical constitution of respiration ferment. Science. 1928;68:437–443


This study provided evidence that ALA and its reduced form can induce cancer cell death by a prooxidant mechanism that is initiated by an increased uptake of oxygen into the mitochondrion.

Zachar Z, Marecek J, Madeo C, et al. Lipoic Acid causes disruption of tumor metabolism and this is followed by cell death by multiple, pathways, including apoptosis and necrosis.


Kisurina-Evgener’eva OF, Dnischenko GE. Alpha-lipoic acid triggers elimination of cells with abnormal nuclei in human carcinoma epidermoid cell line Tsiotologia. 2015;32(3):225-34.

Alpha-lipoic acid induces apoptosis and necrosis in hepatocellular carcinoma cells.

Alpha-lipoic acid not only triggered apoptosis of carcinoma cells, but it also activated the mechanism of elimination of other cells with abnormal chromosome number.


Alpha-lipoic acid stimulates apoptosis in human breast cancer cells.

and


Alpha-lipoic acid induces apoptosis of lung cancer cells.
Non-Standard Cancer Protocol

- Intravenous Alpha Lipoic Acid (ALA) (Bartter and Berkson).
- Intravenous Vitamin C. (after Riordan and Cathcart)
- Low Dose Naltrexone (LDN) (after Zagon and Bihari.)
- Hydroxycitrate (HCA) (after Schwartz L.).
- Healthy diet and life style.
- Supplements (artemesinin, curcumin, etc)
- Prescription drugs (metformin, alprazolam, cimetidine, mebendazole, etc.)

Low Dose Naltrexone (LDN)

- 1.5 to 4.5 mg. LDN at hs
- Fools the brain. Not enough endogenous opiates in blood stream.
- In AM, flood of endogenous opiates released.
- At least one of the opiates, met-enkephalin binds to cancer cell receptors and promotes apoptosis.

Several papers by Ian Zagon and associates.

The T17 cell (Th17) produces interleukin 17 (IL 17).

These cells produce tissue injury by inflammatory processes in Crohn’s disease, juvenile diabetes, MS, rheumatoid arthritis, SLE, etc.

Normally, Th17 cells supplies anti-microbial immunity to epithelial and mucosal tissues by producing interleukin 22, etc. which stimulates epithelial cells to produce inflammatory proteins to kill microbes.

LDN down regulates Th17.

The metabolic effect of adding Hydroxycitrate to alpha lipoic acid allows the reprogramming of cancer cells into oxidative aerobic metabolism rather than anaerobic metabolism.

This should limit the availability of compounds necessary for the growth of cancer.
Alpha Lipoic Acid and Hydroxycitrate target at least four major enzymes in the metabolism of glucose.

- Pyruvate Dehydrogenase Kinase
- ATP Citrate Lyase
- Alpha-amylase
- Alpha-glucosidase

Hydroxycitrate (HCA) down regulates ATP Citrate Lyase (ACL).

ACL limits the conversion of cytoplasmic Citrate into Acetyl CoA available for the synthesis of Lipids and carbohydrate metabolism.

Studies of HCA have produced results that indicate a potential for modulation of lipid and carbohydrate metabolism in cancer cells.

Alpha Lipoic Acid (ALA) inhibits Pyruvate Dehydrogenase Kinase (PDK) (the enzyme that stops Pyruvate Dehydrogenase).

More available Pyruvate Dehydrogenase (PDH), results in the increased Pyruvate being directed into the Krebs Cycle over the conversion of Pyruvate to Lactate.

“The long-term survival of a patient with pancreatic cancer and metastases to the liver”

Berkson BM, Rubin DM, and Berkson AJ
Integrative Cancer Therapies
Volume 5, Number 3, March 2006

We published the first human study that demonstrated the therapeutic effects of ALA combined with LDN for cancer.
Hepatocellular Carcinoma following Hepatitis C
Mrs. JAL
60 year old RN

Mrs. JAL October 2006
Mr. JT Renal Cell Carcinoma

- Diagnosis June, 2008: Urinating blood.
- CT mass L kidney with possible mets to lung.
- Nephrectomy L kidney.
- MD Anderson administered biological response modifiers and chemotherapeutics. TS continued to deteriorate. No effect on JT's RCC.
- JT told to get his affairs in order, no hope for survival June, 2010.
- JT presents on August 16, 2010.
- Put on clinic protocols.
- July 2015, healthy, working, with no signs of disease.

Burton M. Berkson, Daniel M. Rubin, and Arthur J. Berkson

Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic Pancreatic Cancer:
A Report of 3 New Cases

August 2014
Reversal of signs and symptoms of a B-cell lymphoma in a patient using low-dose naltrexone.

Cancer Case Histories

Mrs. MC

68 yo woman with breast cancer.
Refused Surgery, Chemotherapy, and Radiation.
Pathology-Invasive ductal adenocarcinoma Nottingham grade 2/3,
Estrogen +
Progesterone receptor -, pagetoid spread to skin
Metastatic to L axilla lymph nodes
March 15, 2013

July 2013

August 14, 2013

May 14, 2013—September 23, 2013

- Ca 27.29—60—39.5—16—11.5
- Ca 15.3—27.5—19.6—7.3
Lipoic Acid Plus Low-Dose Naltrexone Reviewed for Cancer Treatment

- NCI staff and invited guests listen to Drs. Berkson and Donahue discuss their research and treatments on March 19, 2012
- A panel of researchers and clinicians was convened by the National Cancer Institute (NCI) for presentations and a roundtable discussion about "The State of the Science of Alpha-Lipoic Acid plus Low-Dose Naltrexone for the Treatment of Cancer." The meeting was hosted by the Cancer Therapy Evaluation Program (CTEP), both part of the NCI Division of Cancer Treatment and Diagnosis (DCTD). The meeting provided an opportunity for NCI staff and outside experts to review and discuss case reports from Dr. Burton M. Berkson, an integrative medicine physician and Ph.D. in Biological Sciences, and Adjunct Professor. Dr. Berkson presented on his experience treating patients with alpha-lipoic acid plus low-dose naltrexone for various cancers and autoimmune diseases. The group also heard from Dr. Renee N. Donahue, (Zagon Group) Research Fellow at NCI about her pre-clinical research on the efficacy and proposed mechanism of action of LDN for the treatment of cancer.

The cases being presented today by Dr. Berkson were submitted and given rigorous scientific evaluation under the NCI Best Case Series (BCS) protocol. The ultimate goal is to identify those integrative medicine interventions that have enough evidence to support NCI-initiated research.

Dr. Berkson reported that a combination of ALA (intravenously and orally) and LDN (orally), along with diet, vitamins, and lifestyle changes caused several cancers to go dormant.

Earlier in his medical career, Dr. Berkson published papers using ALA to repair liver damage in patients from mushroom poisoning and chronic infections with hepatitis C virus.

He also cited a number of research articles in European medical journals showing ALA’s beneficial effects on cancer.

Routes of Administration of Alpha Lipoic Acid

- Oral power in capsule.
- Tablet
- Liposomal Alpha Lipoic Acid (phospholipids from soy lecithin)
- Intra Muscular Alpha Lipoic Acid dissolved in Trometamol
- Intravenous Alpha Lipoic Acid dissolved with sodium hydroxide and buffered and delivered in DSW or Normal Saline

Europe and Asia very interested in Alpha lipoic acid. Very little interest in the United States.

What about ALA/N for systemic lupus erythematosus and rheumatoid arthritis?
Summary
ALA is a requisite for aerobic cell life.
because ALA is essential for the conversion of pyruvate to acetyl Co A in the mitochondrion.
ALA is the rate-limiting factor for the production of energy from our cells.
ALA inhibits pyruvate dehydrogenase kinase.
ALA forces cells from an anaerobic metabolism into aerobic metabolism.
ALA has many uses in human medicine.
The efficacy, the apparent lack of toxicity, the long clinical track records of this agent in human medicine, all points toward the need for a clinical trial.
Why aren't there any large scale clinical trials? The agent has too many successful indications.
Companies are working hard to change the alpha lipoic molecule so it can be used as a patented drug and not as useful for so many indications, however, up until now, the corrupted molecules don’t work nearly as well as the natural molecule.

Most of the patients that I see have hepatitis C, diabetes complications, SLE, RA, etc.
Patients sign informed consent forms.
Conventional therapies explained carefully with complete objectivity.
Most cancer patients that I see are end stage. They are told by their oncologist that nothing medically can be done.
This lecture is just my experience and is not an authorization for others to experiment with these protocols.

Books describing my therapies
Also type in Berkson BM on Google, Google Scholar, or PubMed

Thank you for your attention!
Any questions?

Burton M. Berkson MD MS PhD
The Integrative Medical Center of NM
Las Cruces, NM 88011
bberkson@nmsu.edu